CH682803A5 - Use of panthenol, pantetheine or pantothenate, capable of stimulating endogeneous cortico-steroid biosynthesis - in compsn. for treating e.g. bronchial asthma, rheumatism, hay fever or osteoarthritis - Google Patents

Use of panthenol, pantetheine or pantothenate, capable of stimulating endogeneous cortico-steroid biosynthesis - in compsn. for treating e.g. bronchial asthma, rheumatism, hay fever or osteoarthritis Download PDF

Info

Publication number
CH682803A5
CH682803A5 CH41393A CH41393A CH682803A5 CH 682803 A5 CH682803 A5 CH 682803A5 CH 41393 A CH41393 A CH 41393A CH 41393 A CH41393 A CH 41393A CH 682803 A5 CH682803 A5 CH 682803A5
Authority
CH
Switzerland
Prior art keywords
bronchial asthma
compsn
panthenol
diseases
osteoarthritis
Prior art date
Application number
CH41393A
Other languages
German (de)
Inventor
Georg Dr Kunovits
Original Assignee
Georg Dr Kunovits
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georg Dr Kunovits filed Critical Georg Dr Kunovits
Priority to CH41393A priority Critical patent/CH682803A5/en
Publication of CH682803A5 publication Critical patent/CH682803A5/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The use of panthenol (I), pantetheine (II) or pantothenic acid salts (III) is claimed for prepn. of a compsn. for treatment of diseases, esp. neurodermatitis, bronchial asthma, rheumatic diseases, hay-fever or sinusitis maxillaris. Also claimed is a compsn., for treating diseases (esp. as above) contg. a unit dose of 500mg of calcium pantothenate (IIIa), specifically for oral or parenteral admin. USE/ADVANTAGE - (I)-(III) stimulate endogenous corticosteroid biosynthesis, and increase blood levels of adrenocorticotropic hormone (ACTH) and cortisol in humans and animals. They are thus useful for therapy of disorders treatable with corticosteroids, e.g. neurodermatitis, bronchial asthma, chronic polyarthritis, osteoarthritis, sporting injuries, hay fever and chronic recurrent sinusitis maxillaris.

Description

1 1

CH 682 803 A5 CH 682 803 A5

2 2nd

Beschreibung description

Das Acetyl-Coenzym A (Acetyl-CoA) stellt eine biologisch aktive Form der Pantothensäure dar (Fig. 1). Coenzym A wird in der Zelle aus Pantothensäure gebildet und nimmt eine zentrale Stellung im Intermediärstoffwechsel ein (Schema 1). Es bewirkt in acetylierter Form (Acetyl-Coenzym A) die Synthese von Fettsäuren, Cholesterin und Cortico-steroiden. Pantothensäure-Mangel zieht eine verminderte endogene Corticosteroid-Produktion nach sich. The acetyl-coenzyme A (acetyl-CoA) is a biologically active form of pantothenic acid (Fig. 1). Coenzyme A is formed in the cell from pantothenic acid and plays a central role in the intermediate metabolism (Scheme 1). In acetylated form (acetyl-coenzyme A) it effects the synthesis of fatty acids, cholesterol and cortico-steroids. Pantothenic acid deficiency leads to reduced endogenous corticosteroid production.

Pantothensäure wird in Form ihrer Salze und Derivate (Panthenol, Pantethein, Na- oder Kalziumpan-tothenat) verabreicht, die nach oraler Gabe dieselben physiologischen Wirkungen wie Pantothensäure besitzen. Pantothenic acid is administered in the form of its salts and derivatives (panthenol, pantethein, sodium or calcium pantothenate), which after oral administration have the same physiological effects as pantothenic acid.

Pantothensäure-Entzug bei der Ratte bewirkte, dass Pantothenic acid withdrawal in the rat caused that

- der Cholesterin-Gehait der Nebennieren (Cholesterin ist die Vorstufe zu Cortisol) bei den Panto-thensäure-Mangel-Tieren um 76% sank (Fig. 2) the cholesterol content of the adrenal glands (cholesterol is the precursor to cortisol) decreased by 76% in the pantothenic acid-deficient animals (FIG. 2)

- die Mangeltiere nur etwa die Hälfte der ursprünglichen Corticosteroid-Menge synthetisierten (Fig. 3) the deficient animals synthesized only about half of the original amount of corticosteroid (FIG. 3)

- das Muster der ausgeschiedenen 17-Ketosteroide völlig verändert wurde (Fig. 3). - The pattern of the excreted 17-ketosteroids was completely changed (Fig. 3).

Hohe Dosen von Pantothensäure stimulieren die Corticosteroid-Synthese bei der Ratte. High doses of pantothenic acid stimulate corticosteroid synthesis in the rat.

- Fig. 4 zeigt, dass die intramuskuläre Gabe von Natriumpantothenat innerhalb von sechs Stunden eine beinahe 100%-ige Erhöhung des Corticoste-roid-Gehaltes in den Nebennieren bewirkte. 4 shows that intramuscular administration of sodium pantothenate brought about an almost 100% increase in the corticosteroid content in the adrenal glands within six hours.

Hohe Dosen von Pantothensäure stimulieren die endogene Corticosteroid-Synthese auch beim Menschen: High doses of pantothenic acid also stimulate endogenous corticosteroid synthesis in humans:

- Fig. 5 zeigt eine alters- und geschlechtsspezifische Abhängigkeit der Pantothensäure-induzierten Stimulierung der Corticosteroid-Synthese. 5 shows an age-specific and gender-specific dependency of pantothenic acid-induced stimulation of corticosteroid synthesis.

- Fig. 6 zeigt, dass die Plasmaspiegel von Cortisol und ACTH («âdrenosorticoîropic hormon») signifikant erhöht sind. Diese Erhöhung bleibt aber innerhalb der physiologischen Grenzen, d.h. hohe Dosen von Pantothensäure lösen keine unspezifischen, Stress-ähnliche Reaktionen aus. Befürchtungen, dass hohe Dosen von Pantothensäure-Derivaten eine Überproduktion an Steroiden bewirken könnten, sind völlig unbegründet. Eine negative Rückkopplung mit Cortisol als ACTH-Hemmer sorgt für Verhinderung der Überproduktion (Fig. 7). 6 shows that the plasma levels of cortisol and ACTH (“adrenosorticoîropic hormone”) are significantly increased. However, this increase remains within the physiological limits, i.e. high doses of pantothenic acid do not trigger unspecific, stress-like reactions. Fears that high doses of pantothenic acid derivatives could cause steroid overproduction are completely unfounded. Negative feedback with cortisol as an ACTH inhibitor prevents overproduction (FIG. 7).

- Patienten mit Neurodermitis erhielten Kalzium-Pantothenat (2 x 500 mg täglich). Nach vier Wochen Behandlung erhöhten sich die Blutspiegel von ACTH signifikant. - Patients with neurodermatitis received calcium pantothenate (2 x 500 mg daily). After four weeks of treatment, blood levels of ACTH increased significantly.

Klinische Untersuchungen haben gezeigt, dass die stimulierende Wirkung von Pantothensäure auf die Blutspiegel von ACTH und Cortisol, bei der Behandlung von Krankheiten, die mit Corticosteroiden therapierbar sind, anwendbar ist. Beispiele: Clinical studies have shown that the stimulating effect of pantothenic acid on the blood levels of ACTH and cortisol can be used in the treatment of diseases which can be treated with corticosteroids. Examples:

- Patienten mit Neurodermitis wurden mit 2 x 500 mg Kalziumpantothenat täglich behandelt. Der Juckreiz war innerhalb von einigen Wochen vollkommen verschwunden. Die anderen Symptome hatten sich in der Mehrheit der Fälle ebenfalls verbessert. Diese Studie zeigt, dass Kalziumpantothenat, verabreicht in Tablettenform täglich, in der Lage ist, die - Patients with neurodermatitis were treated with 2 x 500 mg calcium pantothenate daily. The itching was completely gone within a few weeks. The other symptoms had also improved in the majority of the cases. This study shows that calcium pantothenate, administered in tablet form daily, is capable of that

Symptome von Neurodermitis wesentlich zu verbessern und die Krankheit unter Kontrolle zu halten. Significantly improve symptoms of atopic dermatitis and keep the disease under control.

- Patienten mit Asthma bronchiale wurden mit 2 x 500 mg Kalziumpantothenat behandelt. Die Patienten blieben während der dreimonatigen Behandlung anfallsfrei. - Patients with bronchial asthma were treated with 2 x 500 mg calcium pantothenate. The patients remained seizure-free during the three-month treatment.

- Patienten mit chronischer Polyarthritis wurden mit Kalziumpantothenat (2 x 500 mg täglich) behandelt. In der Mehrheit der Fälle haben sich die Krankheitssymptome während der Behandlung kontinuierlich verbessert. - Patients with chronic polyarthritis were treated with calcium pantothenate (2 x 500 mg daily). In the majority of cases, the symptoms of the disease have improved continuously during treatment.

- Patienten mit Osteoarthrose wurden mit Kalziumpantothenat (2 x 500 mg täglich) behandelt. In der Mehrheit der Fälle haben sich die Krankheitssymptome kontinuierlich verbessert. - Patients with osteoarthritis were treated with calcium pantothenate (2 x 500 mg daily). In the majority of cases, the symptoms of the disease have improved continuously.

- Patienten mit Sportverletzungen wurden während zwei Wochen mit Kalziumpantothenat (2 x 500 mg täglich) behandelt. In den meisten Fällen haben sich die Symptome verbessert oder sind ganz verschwunden. - Patients with sports injuries were treated with calcium pantothenate (2 x 500 mg daily) for two weeks. In most cases the symptoms have improved or have disappeared completely.

- In mehreren Fällen wurde Kalziumpantothenat (500 mg täglich) prophylaktisch zur Verhinderung von Heuschnupfen mit Erfolg eingesetzt. - In several cases calcium pantothenate (500 mg daily) was used prophylactically to prevent hay fever.

- Patienten mit chronisch rezidivierenden Sinusitis maxillaris wurden während 6-10 Wochen mit Kalziumpantothenat (2 x 500 mg täglich) behandelt. In 70% der Fälle wurde eine wesentliche Verbesserung der Symptome festgestellt. - Patients with chronic recurrent maxillary sinusitis were treated with calcium pantothenate (2 x 500 mg daily) for 6-10 weeks. Significant improvement in symptoms was noted in 70% of cases.

Claims (3)

PatentansprücheClaims 1. Verwendung von Panthenol oder Pantethein oder Salze der Pantothensäure zur Herstellung eines Mittels zur Behandlung von Krankheiten, insbesondere Neurodermitis, Asthma bronchiale, Erkrankungen des rheumatischen Formenkreises, Heuschnupfen und Sinusitis maxillaris.1. Use of panthenol or pantethine or salts of pantothenic acid for the preparation of an agent for the treatment of diseases, in particular neurodermatitis, bronchial asthma, rheumatic diseases, hay fever and maxillary sinusitis. 2. Mittel zur Behandlung von Krankheiten, insbesondere Neurodermitis, Asthma bronchiale, Erkrankungen des rheumatischen Formenkreises, Heuschnupfen und Sinusitis maxillaris, dadurch gekennzeichnet, dass es als Einzeldosis 500 mg Kalziumpantothenat enthält.2. Means for the treatment of diseases, in particular neurodermatitis, bronchial asthma, diseases of the rheumatic type, hay fever and maxillary sinus, characterized in that it contains 500 mg of calcium pantothenate as a single dose. 3. Mittel nach Anspruch 2 in oral oder parenteral verabreichbarer Form.3. Composition according to claim 2 in orally or parenterally administrable form. 55 1010th 1515 2020th 2525th 3030th 3535 4040 4545 5050 5555 6060 6565 22nd
CH41393A 1993-02-11 1993-02-11 Use of panthenol, pantetheine or pantothenate, capable of stimulating endogeneous cortico-steroid biosynthesis - in compsn. for treating e.g. bronchial asthma, rheumatism, hay fever or osteoarthritis CH682803A5 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CH41393A CH682803A5 (en) 1993-02-11 1993-02-11 Use of panthenol, pantetheine or pantothenate, capable of stimulating endogeneous cortico-steroid biosynthesis - in compsn. for treating e.g. bronchial asthma, rheumatism, hay fever or osteoarthritis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH41393A CH682803A5 (en) 1993-02-11 1993-02-11 Use of panthenol, pantetheine or pantothenate, capable of stimulating endogeneous cortico-steroid biosynthesis - in compsn. for treating e.g. bronchial asthma, rheumatism, hay fever or osteoarthritis

Publications (1)

Publication Number Publication Date
CH682803A5 true CH682803A5 (en) 1993-11-30

Family

ID=4186467

Family Applications (1)

Application Number Title Priority Date Filing Date
CH41393A CH682803A5 (en) 1993-02-11 1993-02-11 Use of panthenol, pantetheine or pantothenate, capable of stimulating endogeneous cortico-steroid biosynthesis - in compsn. for treating e.g. bronchial asthma, rheumatism, hay fever or osteoarthritis

Country Status (1)

Country Link
CH (1) CH682803A5 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019359A2 (en) * 1999-09-16 2001-03-22 Britannia Pharmaceuticals Limited Medicaments containing pantothenic acid for the treatment of inflammatory joint disease
WO2009010707A1 (en) * 2007-07-13 2009-01-22 Prototype Bioforum Limited Injectable pharmaceutical compositions containing panthenol

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019359A2 (en) * 1999-09-16 2001-03-22 Britannia Pharmaceuticals Limited Medicaments containing pantothenic acid for the treatment of inflammatory joint disease
GB2355930A (en) * 1999-09-16 2001-05-09 Britannia Pharmaceuticals Ltd Injection of pantothenic acid for relief of pain in joints
WO2001019359A3 (en) * 1999-09-16 2002-10-03 Britannia Pharmaceuticals Ltd Medicaments containing pantothenic acid for the treatment of inflammatory joint disease
US8614249B2 (en) 1999-09-16 2013-12-24 Prototype Bioforum Ltd. Medicaments containing pantothenic acid
WO2009010707A1 (en) * 2007-07-13 2009-01-22 Prototype Bioforum Limited Injectable pharmaceutical compositions containing panthenol

Similar Documents

Publication Publication Date Title
DE69801047T2 (en) NUTRITIONAL SUPPLEMENT
DE69629273T2 (en) Compositions containing propionyl-L-carnitine and hydroxycitric acid or pantothenic acid
DE69618158T2 (en) Pharmaceutical composition containing an alkanoyl-L-carnitine in combination with a polyunsaturated fatty acid of the omega-3 series for the prevention and treatment of disorders of the fat metabolism
DE69814834T2 (en) NUTRITIONAL COMPOSITION TO IMPROVE CELL ENERGY
US5240961A (en) Method of treating reduced insulin-like growth factor and bone loss associated with aging
DE69828881T2 (en) COMPOSITION TO TREAT DISORDERS OF HUMAN HEALTH IN HEALTHY INDIVIDUALS
DE69420746T2 (en) MEDICINES AGAINST STRESS, INTERFERENCE AND AGING AND METHOD FOR THE PRODUCTION THEREOF
DE60207877T2 (en) Composition containing procyanidins for reducing appetite in mammals
EP0046167A1 (en) Nutrient solution for complete extra-buccal feeding and for an enhanced production of energy, and manufacturing process
DE69820029T2 (en) Combined composition consisting of L-carnitine or L-alkanoyl carnitine, a glycosaminoglycan and / or one of its components
US6436946B1 (en) Xanthine-containing compositions for oral administration and uses related thereto
DE60210488T2 (en) USE OF HYDROXYLIC ACID AND SIMILAR COMPOUNDS IN THE MANUFACTURE OF MEDICAMENTS
DE60103055T2 (en) NUTRITIONAL SUPPLEMENT FOR IMPROVING MUSCLE ENERGY METABOLISM, CONTAINING ALKANOYL-CARNITINE AND RIBOSE
CH682803A5 (en) Use of panthenol, pantetheine or pantothenate, capable of stimulating endogeneous cortico-steroid biosynthesis - in compsn. for treating e.g. bronchial asthma, rheumatism, hay fever or osteoarthritis
DE69315162T2 (en) Use of L-carnitine and acyl-L-carnitine for the treatment of patients suffering from AIDS-related syndromes and of asymptomatic HIV-seropositive patients
US5304574A (en) Methods of treatment of clinical conditions using pantothenic acid
WO2012076680A1 (en) Combination preparation for improving female fertility
US20030165585A1 (en) Xanthine-containing compositions for oral administration and uses related thereto
EP1789026B1 (en) Method for systemic bio-correction of an organism
RU2698396C1 (en) Pharmaceutical composition for parenteral drop introduction
CARLSSON et al. A comparative study on the mode of action of dihydrotachysterol and vitamin D on the calcium metabolism
DE3625459A1 (en) Ubiquinone-containing pharmaceutical composition for oral administration
DE69824718T2 (en) PHARMACEUTICAL COMPOSITION FOR PROMOTING OSTEOBLASTEN CONTAINING A CARNITINE COMPOUND AND DHEA OR DHEA-S
DE2429034A1 (en) NUTRITIONAL LIQUID FOR PARENTERAL TRACKING
RU2745868C1 (en) Method for accelerating regeneration processes in damaged peripheral nerves

Legal Events

Date Code Title Description
PL Patent ceased